Secukinumab efficacy in the treatment of various types of psoriasis: A case series
Open Access
- 15 December 2021
- journal article
- Published by Scientific Scholar
- Vol. 3, 108-112
- https://doi.org/10.25259/aujmsr_31_2021
Abstract
The aim of this article is to describe our experience in a tertiary care medical college hospital with secukinumab in the treatment of various types of psoriasis as a case series of 10 patients. All the patients showed significant improvement in psoriasis area severity index and dermatology life quality index scores with no major adverse event reported during the period of study for 6 months duration. Secukinumab may be effective and safe for the treatment of all types of psoriasis with rapid onset of action and improvement in the quality of life.Keywords
This publication has 13 references indexed in Scilit:
- Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta–analysis of randomised controlled trialsRMD Open, 2019
- Secukinumab dose optimization in adult psoriasis patients: A retrospective, multicenter case seriesJAAD Case Reports, 2018
- Recent understanding of the etiopathogenesis of psoriasisIndian Journal of Paediatric Dermatology, 2017
- Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 studyIndian Dermatology Online Journal, 2017
- Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trialJournal of the American Academy of Dermatology, 2016
- Safety of secukinumab in the treatment of psoriasisExpert Opinion on Drug Safety, 2016
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 TrialsThe New England Journal of Medicine, 2014
- Treatment with the Interleukin-17A-Blocking Antibody Secukinumab Does Not Interfere with the Efficacy of Influenza and Meningococcal Vaccinations in Healthy Subjects: Results of an Open-Label, Parallel-Group, Randomized Single-Center StudyClinical and Vaccine Immunology, 2012
- Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding studyBritish Journal of Dermatology, 2012
- Psoriasis in India: Prevalence and patternIndian Journal of Dermatology, Venereology and Leprology, 2010